German radiopharma Ariceum unveils early efficacy signal for lead asset in neuroendocrine cancers
寡核苷酸临床研究
Berlin-based Ariceum Therapeutics has revealed positive data from a Phase I/II trial of its radiopharmaceutical therapy, satoreotide, in neuroendocrine tumors, two years after the biotech made its debut.
Satoreotide uses the radioactive isotope lutetium to antagonize the somatostatin receptor 2 (SSTR2). Ariceum launched in 2021 after
acquiring full rights
to satoreotide from Ipsen.
The Phase I/II trial
studied satoreotide
in people with previously treated, progressive SSTR2-positive NETsSSTR2-positive NETs. The trial’s part A comprised 15 patients who completed three cycles of satoreotide at a fixed activity level, while part B included 25 patients who got one to five cycles of the therapy at different activity levels.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。